BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 34076851)

  • 1. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
    Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
    Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
    Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
    J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease.
    Seko Y; Yamaguchi K; Tochiki N; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Umemura A; Moriguchi M; Tanaka S; Mori K; Okanoue T; Itoh Y
    Liver Int; 2020 Jul; 40(7):1686-1692. PubMed ID: 32342668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort
    Anstee QM; Darlay R; Cockell S; Meroni M; Govaere O; Tiniakos D; Burt AD; Bedossa P; Palmer J; Liu YL; Aithal GP; Allison M; Yki-Järvinen H; Vacca M; Dufour JF; Invernizzi P; Prati D; Ekstedt M; Kechagias S; Francque S; Petta S; Bugianesi E; Clement K; Ratziu V; Schattenberg JM; Valenti L; Day CP; Cordell HJ; Daly AK;
    J Hepatol; 2020 Sep; 73(3):505-515. PubMed ID: 32298765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric non-alcoholic fatty liver disease and kidney function: Effect of
    Di Sessa A; Umano GR; Cirillo G; Passaro AP; Verde V; Cozzolino D; Guarino S; Marzuillo P; Miraglia Del Giudice E
    World J Gastroenterol; 2020 Sep; 26(36):5474-5483. PubMed ID: 33024398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PNPLA3 risk allele is associated with risk of hepatocellular carcinoma but not decompensation in compensated cirrhosis.
    Urias E; Tedesco NR; Burkholder DA; Moran IJ; Miller MJ; Jasty VSJ; Patil S; Zoellner S; Wijarnpreecha K; Chen VL
    Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38780253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease.
    Koo BK; Joo SK; Kim D; Bae JM; Park JH; Kim JH; Kim W
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1277-1285. PubMed ID: 29193269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.
    Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
    Gene; 2022 Apr; 820():146235. PubMed ID: 35143946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non-alcoholic fatty liver disease in children.
    Lee KJ; Moon JS; Kim NY; Ko JS
    Pediatr Obes; 2022 Feb; 17(2):e12852. PubMed ID: 34490745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population.
    Cavalcante LN; Porto J; Mazo D; Longatto-Filho A; Stefano JT; Lyra AC; Carrilho FJ; Reis RM; Alves VAF; Sanyal AJ; Oliveira CP
    Ann Hepatol; 2022; 27(6):100728. PubMed ID: 35710086
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Kalinowski P; Smyk W; Nowosad M; Paluszkiewicz R; Michałowski Ł; Ziarkiewicz-Wróblewska B; Weber SN; Milkiewicz P; Lammert F; Zieniewicz K; Krawczyk M
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.
    Wu JT; Liu SS; Xie XJ; Liu Q; Xin YN; Xuan SY
    Lipids Health Dis; 2020 Feb; 19(1):29. PubMed ID: 32093693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Validation of a Scoring System, Based on Genetic and Clinical Factors, to Determine Risk of Steatohepatitis in Asian Patients with Nonalcoholic Fatty Liver Disease.
    Koo BK; Joo SK; Kim D; Lee S; Bae JM; Park JH; Kim JH; Chang MS; Kim W
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2592-2599.e10. PubMed ID: 32062042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD.
    Vilar-Gomez E; Pirola CJ; Sookoian S; Wilson LA; Liang T; Chalasani N
    Clin Transl Gastroenterol; 2021 Sep; 12(9):e00400. PubMed ID: 34506332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of HSD17B13 rs72613567:TA with non-alcoholic fatty liver disease in Hispanics/Latinos.
    Kallwitz E; Tayo BO; Kuniholm MH; Daviglus M; Zeng D; Isasi CR; Cotler SJ
    Liver Int; 2020 Apr; 40(4):889-893. PubMed ID: 31965669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan.
    Akuta N; Kawamura Y; Arase Y; Suzuki F; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Ikeda K; Kumada H
    Gut Liver; 2016 May; 10(3):437-45. PubMed ID: 26610348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C.
    Petta S; Maida M; Grimaudo S; Pipitone RM; Macaluso FS; Cabibi D; Cammà C; Di Marco V; Sferrazza S; Craxì A
    Liver Int; 2016 Feb; 36(2):198-204. PubMed ID: 26259026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of candidate gene variants in modulating the risk and severity of alcoholic hepatitis.
    Beaudoin JJ; Liang T; Tang Q; Banini BA; Shah VH; Sanyal AJ; Chalasani NP; Gawrieh S
    Alcohol Clin Exp Res; 2021 Apr; 45(4):709-719. PubMed ID: 33616244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.